- Datum17.03.2025
- Uhrzeit08:00 - 09:00 Uhr
- Veranstalter
XTB
Ascendis Pharma A/S Nav.-Akt.(Spons.ADRs)/1 DK 1 Chart

Charts analysieren
wie die Profis?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse und handle direkt aus dem Chart bei Deinem Broker.
Chart analysieren
Ascendis Pharma A/S Nav.-Akt.(Spons.ADRs)/1 DK 1 Realtime-Kurs
Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
---|---|---|---|---|---|---|
L&S | VK | |||||
Tradegate | VK | |||||
Stuttgart | VK |
Passende Produkte
WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
---|
Wertentwicklung (Nasdaq)
Wikifolio
Passender Service zu Ascendis Pharma A/S Nav.-Akt.(Spons.ADRs)/1 DK 1
Webinar zu Ascendis Pharma A/S Nav.-Akt.(Spons.ADRs)/1 DK 1
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)111,090-158,000
- Jahrestief / Hoch ($)118,030-158,000
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Ascendis Pharma A/S Nav.-Akt.(Spons.ADRs)/1 DK 1
Termine von Ascendis Pharma A/S Nav.-Akt.(Spons.ADRs)/1 DK 1
Beschreibung
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.